Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood（2023）

引用 2|浏览16

暂无评分

摘要

•Addition of oral azacitidine to CHOP as initial therapy is safe, and induces high rates of CR in patients with PTCL-TFH.•Integrative analyses suggest that azacitidine priming promotes apoptosis and inflammation within the lymphoma tumor microenvironment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要